Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Biol Psychiatry. 2016 Mar 31;81(1):31–42. doi: 10.1016/j.biopsych.2016.03.2104

Table 1.

Effect of previous antipsychotic exposure on unmasked BPND Binding potentials from α-MPT depletion studies

Rx-free v Rx-naïve Rx-free v HC Rx-naïve v HC
HC SZ p Rx-free Rx-naïve p p p
[123I]IBZM SPECT: Striatuma n=18 n=18 n=10 n=8
 BPNDBsl 0.722 ± 0.091 0.751 ± 0.103 0.38 0.779 ± 0.122 0.716 ± 0.066 0.21 0.17 0.87
 BPNDDpl* 0.787 ± 0.096 0.889 ± 0.124 0.009 0.930 ± 0.147 0.837 ± 0.062 0.12 0.004** 0.19
[11C]Raclopride PET: Striatumb n=18 n=18 n=12 n=6
 BPNDBsl 2.53 ± 0.25 2.56 ± 0.52 0.83 2.71 ± 0.50 2.25 ± 0.44 0.08 0.19 0.07
 BPNDDpl* 2.81 ± 0.23 2.94 ± 0.54 0.35 3.12 ± 0.52 2.59 ± 0.42 0.048 0.04** 0.12
[11C]Raclopride PET: Rostral caudateb n=18 n=18 n=12 n=6
 BPNDBsl 2.40 ± 0.23 2.41 ± 0.45 0.89 2.54 ± 0.43 2.16 ± 0.42 0.10 0.25 0.10
 BPNDDpl* 2.61 ± 0.27 2.77 ± 0.49 0.25 2.91 ± 0.47 2.47 ± 0.43 0.07 0.03** 0.36
a

Abi-Dargham et al., PNAS 2000 (57)

b

Kegeles et al., AGP 2010 (59)

*

Significant one-way ANOVA comparing BPNDDpl for Rx-free, Rx-naïve, and HC (p < 0.05).

**

Significant post-hoc t test for BPNDDpl, Rx-free compared to HC (but not significant for Rx-naive compared to HC).

Abbreviations: D2 binding potential in the baseline state, partially masked by baseline levels of endogenous dopamine (BPNDBsl); Unmasked D2 binding potential in the dopamine-depleted state (BPNDDpl); Healthy control participants (HC); Participants with schizophrenia (SZ); Antipsychotic-free, previously-medicated patients (Rx-free); Antipsychotic-naïve patients (Rx-naïve)